Recovery ⏱ Half-life: ~1 hour FDA-Approved

Teriparatide

Teriparatide (Forteo, PTH 1-34)

Updated March 30, 2026

Evidence at a Glance

Regulatory statusFDA-Approved
Approved as Forteo (recombinant PTH 1-34) for osteoporosis; FDA 2002
Human evidenceExtensive
Animal evidenceExtensive

A recombinant parathyroid hormone (1-34) fragment FDA-approved since 2002, with large randomized trials showing it builds bone and reduces vertebral and non-vertebral fracture risk in osteoporosis.

What the research does not support

  • It is a prescription osteoporosis drug, not a general 'bone or joint healing' peptide, and is not shown to strengthen healthy young bone.
  • Rat carcinogenicity studies raised an osteosarcoma concern that underpinned an FDA boxed warning later removed in 2021 after no human signal emerged.
  • Anabolic bone gains are not indefinite; its labeled use historically carried a limited treatment duration rather than open-ended use.
Half-Life
~1 hour
Purity
Pharmaceutical grade
Mol. Weight
4,117.8 Da
Form
Solution in pre-filled injection pen

What is Teriparatide?

Teriparatide (Forteo) was the first bone anabolic agent approved for osteoporosis (2002), representing a paradigm shift from purely antiresorptive approaches. By stimulating osteoblasts to build new bone rather than simply slowing bone loss, it can restore bone architecture in ways that bisphosphonates cannot.

Dosage Information (Research Use)

20mcg SC once daily in the thigh or abdominal wall. Treatment duration: up to 2 years. Follow with antiresorptive therapy. Prescription medication.

Reconstitution & Handling

Pre-filled pen — no reconstitution.

Half-Life & Pharmacokinetics

~1 hour

Reported Observations in Literature

Leg cramps (3%), nausea (9%), headache (8%), dizziness (8%), orthostatic hypotension (5%), hypercalcemia (11% mild). Black box warning for osteosarcoma (rodent data at 3-60x human doses). Contraindicated in Paget’s disease and prior bone radiation.

Key Research References

  • Neer RM et al. “Effect of parathyroid hormone (1-34) on fractures and bone mineral density.” N Engl J Med. 2001;344:1434-41

How Teriparatide Works

Teriparatide is recombinant human PTH (1-34), the biologically active N-terminal fragment. When administered intermittently (once daily), it paradoxically stimulates bone formation over resorption — a phenomenon called the "anabolic window." This occurs because osteoblasts respond to pulsatile PTH with increased activity, while continuous PTH exposure favors osteoclast activation and bone resorption.

Research Applications

🔬 Osteoporosis treatment
🔬 Bone fracture healing
🔬 Osteogenesis imperfecta

Research Findings

The pivotal fracture prevention trial showed 65% reduction in vertebral fractures and 53% reduction in nonvertebral fractures. Increases BMD by 9-13% at the lumbar spine over 18 months. Sequential therapy with antiresorptive agents after teriparatide is essential to maintain gains.

Dosage & Administration

20mcg SC once daily in the thigh or abdominal wall. Treatment duration: up to 2 years. Follow with antiresorptive therapy. Prescription medication.

Safety & Side Effects

Leg cramps (3%), nausea (9%), headache (8%), dizziness (8%), orthostatic hypotension (5%), hypercalcemia (11% mild). Black box warning for osteosarcoma (rodent data at 3-60x human doses). Contraindicated in Paget's disease and prior bone radiation.

Important: All safety information is derived from published research, primarily animal studies. No controlled human clinical trial data exists unless explicitly noted. This compound is sold for research purposes only.

Quick Facts

Molecular Weight 4,117.8 Da
Half-Life ~1 hour
Purity Pharmaceutical grade
Form Solution in pre-filled injection pen
Storage Refrigerate 2-8°C.

Key Research References

  • Neer RM et al. "Effect of parathyroid hormone (1-34) on fractures and bone mineral density." N Engl J Med. 2001;344:1434-41

Related Peptides

View all →
KLOW
Recovery
KLOW is not a single compound. It is a trade name for a research blend of four peptides,…
View Profile → Buy Now
Vesugen
Recovery
Vascular-targeting tripeptide bioregulator researched for endothelial function and microcirculation support.
View Profile →
Vesilute
Recovery
Bladder-targeting peptide bioregulator researched for urinary tract epithelial support and detrusor muscle function.
View Profile →